Pa Ogasiti 11, Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) idanena kuti kugwiritsa ntchito kwa InxMed mapiritsi a IN10018 kwaperekedwa kuti kugwiritsidwe ntchito pochiza khansa ya m'matumbo ya KRAS G12C yomwe yakula kwambiri kapena yofalikira kwambiri (CRC) yomwe yalandira chithandizo cha mitundu iwiri ya mankhwala.
Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.
Nambala ya Foni: 4008803716
Chizindikiro cha WeChat: 17801183037
Email：myimmnet@163.com
About Ifebemtinib (IN10018)
Ifebemtinib (IN10018) ndi mankhwala oletsa mamolekyulu ang'onoang'ono oletsa FAK, omwe amaperekedwa pakamwa, omwe ali ndi mgwirizano waukulu ndi njira zosiyanasiyana zochiritsira. Mwachipatala, yawonetsa mgwirizano wochiritsira ndi chemotherapy, mankhwala ochizira, ndi ma immunotherapy. Mpaka pano, odwala opitilira 600 athandizidwa ndi chitetezo chabwino komanso kulekerera.
Pa Msonkhano Wapachaka wa ASCO wa 2025, adatulutsa deta yaposachedwa yachipatala kuchokera ku mayeso azachipatala a Phase Ib/II (NCT06166836; NCT05379946) kuti awone momwe ifebemtinib (IN10018) imagwirira ntchito, choletsa cha oral focal adhesion kinase (FAK) chophatikizana ndi garsorasib (D-1533), choletsa cha oral KRAS G12C, mu zotupa zolimba za KRAS G12C mutant.
Deta yachipatala yomwe inaperekedwa pa Msonkhano Wapachaka wa ASCO wa 2025 (Chidule #8629 | Poster Board #109) inaphatikizapo zotsatira kuchokera ku magulu awiri:
Kutsatira deta yolimba ya gulu la anthu omwe ali ndi mkono umodzi mwa odwala khansa ya m'mapapo ya KRAS G12C yosinthika (NSCLC) omwe ali ndi mzere woyamba wa KRAS G12C, mosasamala kanthu za mawonekedwe a PD-L1, omwe adalandira chithandizo cha ifebemtinib + garsorasib.
Gulu la odwala khansa ya m'matumbo yosinthika ya KRAS G12C (CRC) omwe adachiritsidwa kale akuyerekeza ifebemtinib+ garsorasib ndi garsorasib monotherapy.
Mu gulu la NSCLC, kuphatikiza kwa ifebemtinib ndi garsorasib, monga njira yogwiritsira ntchito pakamwa kawiri, yopanda mankhwala a chemotherapy, kunawonetsa phindu lalikulu lachipatala kuphatikizapo kuchuluka kwa mayankho komanso kugwira ntchito kolimba, mosasamala kanthu za PD-L1, ndipo mu gulu la CRC, zotsatira zake zinawonetsa kugwira ntchito bwino kwa ifebemtinib poyerekeza ndi KRAS inhibitor monotherapy.
Mfundo Zazikulu mu NSCLC Yoyamba: Njira Yogwiritsira Ntchito Pakamwa Pawiri Imasonyeza Kugwira Ntchito Kolimba ndi Phindu Lopulumuka Lomwe Likubwera
Pofika pa 31 Marichi, 2025, odwala 33 oyamba a NSCLC, mosasamala kanthu za PD-L1 expression, adalembetsa ndipo adalandira kuphatikiza kwa ifebemtinib ndi garsorasib, ndi kutsatiridwa kwapakati kwa miyezi 16.0. Poyamba kampaniyo idanena kuti Objective Response rate (ORR) ndi 90.3% (deta yomwe yaperekedwa ku ESMO 2024). Deta yotsatira tsopano yafupikitsidwa motere:
Kupulumuka kwapakati kopanda kupita patsogolo (mPFS): miyezi 22.3
Nthawi yapakati ya yankho la DOR (mDOR): miyezi 19.4
Kupulumuka kwapakati (mOS): sikunafike pano, ndi kukwera kwakukulu komanso kosalala komwe kumasonyeza phindu lolimba.
Chodziwika n'chakuti, chithandizochi chinasonyeza kuti chimagwira ntchito bwino nthawi zonse mosasamala kanthu za momwe PD-L1 imagwirira ntchito.
Zomwe Zapezeka mu CRC Yomwe Inachiritsidwa Kale: Kuyesa Kosasinthika Kumatsimikizira Kugwirizana ndi KRAS G12Ci
Pofika pa Epulo 21, 2025, odwala 36 omwe adachiritsidwa kale a CRC adapatsidwa mankhwala osakanikirana a 1:1 kuti alandire kuphatikiza kwa ifebemtinib + garsorasib kapena garsorasib yokha. Odwala onse adawunikidwa ndi radiology ndipo mayankho a antitumor adawunikidwa ndi kufotokozedwa motere:
ORR: 44.4% (yophatikizana) vs. 16.7% (mono)
Chiŵerengero cha matenda (DCR): 100.0% (combo) vs. 77.8% (mono)
mPFS: miyezi 7.7 (yophatikizana) poyerekeza ndi miyezi 4.0 (mono)
mOS: sichinafikebe mu mkono wophatikizana; kulekanitsidwa koyambirira kumawonedwa mu ma curve opulumuka
Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.
Nambala ya Foni: 4008803716
Chizindikiro cha WeChat: 17801183037
Email：myimmnet@163.com
Nthawi yotumizira: Ogasiti-13-2025